7.5 325 Norco: A Comprehensive Guide to Hydrocodone and Acetaminophen Combination

21.05.202128.07.2023 by alexxlab

What are the proper uses of 7.5 325 Norco. How does the combination of hydrocodone and acetaminophen work. What are the dosing guidelines for pain management. What precautions should be taken when using this medication.

Содержание

Understanding 7.5 325 Norco: Composition and Pharmacology

7.5 325 Norco is a potent pain medication that combines two active ingredients: hydrocodone (7.5 mg) and acetaminophen (325 mg). This combination is widely prescribed for moderate to severe pain management, offering a synergistic effect that enhances pain relief while potentially reducing the risk of opioid-related side effects.

Hydrocodone: The Opioid Component

Hydrocodone is a full opioid agonist that primarily interacts with mu-opioid receptors in the body. Its mechanism of action involves:

Inhibition of nociceptive pain reflexes
Induction of profound analgesia
Inhibition of neurotransmitter release, including substance P

How quickly does hydrocodone take effect? Hydrocodone reaches maximum serum concentrations within 1 hour of administration. Its elimination half-life ranges from 4 to 6 hours, providing extended pain relief.

Acetaminophen: The Non-Opioid Analgesic

While the exact mechanism of acetaminophen’s analgesic action remains not fully understood, it is believed to work through:

COX inhibition
Activation of descending serotonergic inhibitory pathways in the CNS
Inhibition of the hypothalamic heat-regulating center (for antipyretic effects)

Acetaminophen is rapidly absorbed from the gastrointestinal tract, with a plasma half-life of 1 to 3 hours. Approximately 85% of the drug is eliminated in the urine within 24 hours of administration.

Indications and Therapeutic Uses of 7.5 325 Norco

7.5 325 Norco is primarily indicated for the management of moderate to severe pain. Its efficacy has been demonstrated in various clinical scenarios, including:

Postoperative pain management
Trauma-related pain
Cancer-associated pain
Antitussive therapy (cough suppression)

Is 7.5 325 Norco more effective than placebo? Several randomized studies have shown that the combination of hydrocodone with acetaminophen is significantly more efficacious than placebo in pain management, without substantial increases in adverse effects.

Proper Administration and Dosing Guidelines

The proper administration of 7.5 325 Norco is crucial for achieving optimal pain relief while minimizing the risk of adverse effects. Healthcare providers should carefully consider the following dosing guidelines:

Oral Tablet Formulation

For adults using the oral tablet formulation:

Initial dose: One or two tablets every four to six hours as needed for pain
Maximum daily dosage: Not to exceed eight tablets

Oral Solution Formulation

When using the oral solution (7.5 mg hydrocodone / 325 mg acetaminophen per 15 mL):

Initial dose: One tablespoonful (15 mL) every 4 to 6 hours as needed for pain
Maximum daily dosage: Not to exceed six tablespoonfuls

How should the dosage be adjusted for individual patients? It’s essential to titrate the dose individually, taking into account the severity of pain, patient response, and prior analgesic experience. The goal is to use the lowest effective dose for adequate analgesia.

Pharmacokinetics and Metabolism of 7.5 325 Norco

Understanding the pharmacokinetics of 7.5 325 Norco is crucial for optimizing its therapeutic use and minimizing potential risks.

Hydrocodone Metabolism

Hydrocodone undergoes extensive metabolism in the liver, primarily through the CYP2D6 enzyme pathway. This process converts hydrocodone to its active metabolite, hydromorphone, which contributes significantly to the analgesic effect.

Does genetic variation in CYP2D6 affect hydrocodone efficacy? Indeed, genetic polymorphisms in the CYP2D6 enzyme can influence the metabolism of hydrocodone, potentially affecting its analgesic potency and duration of action in individual patients.

Acetaminophen Metabolism

Acetaminophen is primarily metabolized in the liver through three main pathways:

Glucuronidation (approximately 60% of a therapeutic dose)
Sulfation (approximately 30% of a therapeutic dose)
Oxidation by cytochrome P450 enzymes (less than 10% of a therapeutic dose)

The oxidative pathway produces a potentially toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by conjugation with glutathione. However, in cases of acetaminophen overdose, this pathway can become saturated, leading to hepatotoxicity.

Potential Adverse Effects and Precautions

While 7.5 325 Norco can be highly effective for pain management, it’s essential to be aware of potential adverse effects and take necessary precautions:

Common Side Effects

Constipation
Nausea and vomiting
Drowsiness and sedation
Dizziness
Itching

Serious Adverse Effects

What are the most concerning potential side effects of 7.5 325 Norco? Healthcare providers and patients should be vigilant for:

Respiratory depression
Hepatotoxicity (due to acetaminophen)
Addiction and physical dependence
Serotonin syndrome (when combined with other serotonergic medications)
Adrenal insufficiency

Precautions and Contraindications

7.5 325 Norco should be used with caution in patients with:

History of substance abuse
Respiratory disorders (e.g., COPD, sleep apnea)
Liver or kidney dysfunction
Elderly patients or those with cognitive impairment

The medication is contraindicated in patients with known hypersensitivity to hydrocodone or acetaminophen, as well as in those with severe respiratory depression or acute or severe bronchial asthma in an unmonitored setting.

Drug Interactions and Special Considerations

The combination of hydrocodone and acetaminophen in 7.5 325 Norco can interact with various medications and substances, potentially altering its efficacy or increasing the risk of adverse effects.

Significant Drug Interactions

Benzodiazepines and other CNS depressants: Can enhance respiratory depression
CYP3A4 inhibitors or inducers: May alter hydrocodone metabolism
Monoamine oxidase inhibitors (MAOIs): Can increase the risk of serotonin syndrome
Anticholinergic medications: May increase the risk of urinary retention and severe constipation

How can healthcare providers mitigate the risks associated with these drug interactions? Careful medication reconciliation, dose adjustments, and close monitoring are essential strategies for managing potential interactions.

Special Patient Populations

Certain patient groups require special consideration when prescribing 7.5 325 Norco:

Pregnant women: Use only if the potential benefit justifies the potential risk to the fetus
Breastfeeding mothers: Use with caution, as both hydrocodone and acetaminophen are excreted in breast milk
Pediatric patients: Safety and efficacy not established in children under 18 years of age
Geriatric patients: May require lower initial doses and more frequent monitoring due to increased sensitivity to opioids

Monitoring and Managing Long-Term Use

Long-term use of 7.5 325 Norco requires careful monitoring to ensure continued efficacy and minimize risks associated with chronic opioid therapy.

Regular Assessment and Follow-up

Healthcare providers should implement a structured monitoring plan that includes:

Regular pain assessments and functional evaluations
Screening for signs of misuse, abuse, or addiction
Monitoring for adverse effects, including constipation and respiratory depression
Periodic liver function tests to assess for acetaminophen-related hepatotoxicity

How often should patients on long-term 7.5 325 Norco therapy be reassessed? While individual needs may vary, a general recommendation is to conduct comprehensive evaluations at least every 3 to 6 months, with more frequent follow-ups for high-risk patients or those requiring dose adjustments.

Opioid Rotation and Dose Tapering

In cases where long-term therapy is necessary, healthcare providers should consider:

Opioid rotation to mitigate tolerance and improve pain control
Gradual dose tapering when discontinuing therapy to minimize withdrawal symptoms
Incorporating non-pharmacological pain management strategies

Implementing a multimodal approach to pain management can help reduce reliance on opioid medications and improve overall outcomes for patients requiring long-term pain control.

Patient Education and Safe Use Practices

Proper patient education is crucial for the safe and effective use of 7.5 325 Norco. Healthcare providers should ensure that patients understand:

Key Points for Patient Education

Proper dosing and administration instructions
Potential side effects and when to seek medical attention
Risks of dependence and addiction
Importance of secure storage and proper disposal of unused medication
Dangers of combining with alcohol or other CNS depressants

What strategies can healthcare providers use to enhance patient understanding and compliance? Utilizing written materials, teach-back methods, and involving family members or caregivers in education sessions can improve comprehension and adherence to safe use practices.

Safe Storage and Disposal

Patients should be instructed to:

Store 7.5 325 Norco in a secure, locked location
Keep the medication out of reach of children and pets
Never share their prescription with others
Dispose of unused medication through authorized take-back programs or following FDA-recommended disposal methods

Proper storage and disposal practices play a crucial role in preventing accidental ingestion, diversion, and environmental contamination.

Hydrocodone and Acetaminophen – StatPearls

Continuing Education Activity

Hydrocodone is one of the most common pain medications prescribed by clinicians and one of the most abused by patients. It is a relatively potent drug for moderate-to-severe pain control in postoperative patients, patients with trauma, or patients with cancer. The combination of hydrocodone with acetaminophen is much more efficacious in several randomized studies without any significant changes in adverse effects. Moreover, hydrocodone/acetaminophen has common use as an antitussive agent. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of hydrocodone/acetaminophen so that providers can direct patient therapy to optimal outcomes.

Objectives:

Identify the mechanism of action of hydrocodone/acetaminophen.
Outline the approved uses for initiating hydrocodone/acetaminophen therapy.
Summarize the adverse event profile and contraindications to using hydrocodone/acetaminophen.
Explain interprofessional team strategies for improving care coordination and communication to advance hydrocodone/acetaminophen therapy, improve outcomes, and minimize adverse events and misuse, especially in light of the ongoing opioid crisis.

Access free multiple choice questions on this topic.

Indications

Mechanism of Action

Hydrocodone is a full opioid agonist that interacts with the mu-receptors and, to a lesser extent, with delta receptors in the body. [3] Activated mu-opioid receptors lead to inhibition of nociceptive pain reflexes and induce profound analgesia without affecting other sensory modalities such as touch. Additionally, activated opioid receptors inhibit neurotransmitter release, including substance P.[3] Hydrocodone reaches maximum serum concentrations within 1 hour with an elimination half-life of 4 to 6 hours.[4] Hydrocodone has to be metabolized by CYP2D6 to its active form, hydromorphone.[3]

Acetaminophen’s mechanism of action of analgesia is not fully understood. The hypothesis has been that it results from COX inhibition and activation of descending serotonergic inhibitory pathways in the CNS. Antipyretic effects occur via inhibition of the hypothalamic heat-regulating center. Acetaminophen is readily absorbed from the gastrointestinal tract. Plasma protein binding of acetaminophen is about 10 to 25%. The plasma half-life ranges from 1 to 3 hours; however, it may increase due to liver damage following overdose. Approximately 85% of the drug is eliminated in the urine within 24 hours of administration.[5]

Administration

Hydrocodone and acetaminophen combination is available as oral tablet and oral solution formulation.

Hydrocodone bitartrate 5 mg / acetaminophen 300 mg
Hydrocodone bitartrate 5 mg / acetaminophen 325 mg
Hydrocodone bitartrate 7.5 mg / acetaminophen 300 mg
Hydrocodone bitartrate 7.5 mg / acetaminophen 325 mg
Hydrocodone bitartrate 10 mg / acetaminophen 300 mg
Hydrocodone bitartrate 10 mg / acetaminophen 325 mg
Hydrocodone bitartrate 7.5 mg / acetaminophen 325 mg per 15 mL oral solution

Dosing Regimen for Pain Management

The lowest dose necessary for adequate analgesia is recommended and should be titrated individually for each patient taking into account the severity of pain, response, and prior analgesic experience.
For initial oral tablets therapy, the usual adult dose of hydrocodone and acetaminophen ( 5 mg / 300 mg) is one or two tablets every four to six hours as needed for pain. The total daily dosage should not be more than eight tablets.
For initial oral solution therapy, the usual adult dose of solution ( 7.5mg / 325mg per 15 mL) is one tablespoonful (15 mL) every 4 to 6 hours as needed for pain. The total daily dosage for adults should not be more than six tablespoonfuls.
For the conversion from other opioids to hydrocodone and acetaminophen therapy, it is recommended to underestimate the dose of hydrocodone bitartrate and acetaminophen on 24 hours basis for managing an adverse reaction due to the risk of overdose. The relative bioavailability information is unknown for conversion from extended-release hydrocodone to hydrocodone and acetaminophen therapy. So close monitoring for signs of excessive sedation and respiratory depression is recommended. The dose should be titrated on an individual basis. Continuous reevaluation of the dose of hydrocodone and acetaminophen is needed to maintain adequate pain control, minimize adverse effects, and monitor the development of addiction, abuse, or misuse.
For patients who may have a physical dependence on opioids, abrupt discontinuation of hydrocodone and acetaminophen therapy may result in severe withdrawal symptoms, uncontrolled pain, and suicidal tendency.

Specific Patients Population

Patient with Hepatic Impairment: There is no dose adjustment guidance in the manufacturer label for patients with hepatic impairment. However, initiating therapy with the lowest dose with continuous monitoring is recommended in these patients.
Patient with Renal Impairment: There is no dose adjustment guidance in the manufacturer label for patients with renal impairment. However, 26% of hydrocodone and 85% of acetaminophen are eliminated in the urine, so the drug should be used with caution.
Pregnant Women: It is considered as pregnancy category C medicine. There is a US box warning related to pregnancy. During pregnancy, prolonged use of hydrocodone and acetaminophen can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized early and treated accordingly.
Breastfeeding Women: Hydrocodone and Acetaminophen are present in breast milk. The decision to continue or discontinue breastfeeding during therapy should be based on the risk of infant exposure versus the benefits of breastfeeding and treatment to the mother.[6][7]
Pediatric Patients: The dose of hydrocodone for pediatric patients is titrated based on desired analgesic effect. While considering acetaminophen dose, it is recommended to consider the maximum daily dose of acetaminophen from all other sources like OTC, other prescription, or combination products. The maximum daily dose should not exceed 2000 mg for acetaminophen to minimize hepatotoxicity maximum. Based on the information provided in the hydrocodone and acetaminophen oral solution label, dosing should be calculated as 0.27 mL/kg child weight (equivalent to 0.135 mg/kg hydrocodone and 5.85 mg/kg dose of acetaminophen) whenever possible.
Geriatric Patients: For safety and efficacy, it is recommended to start the initial dose at the lower end of the dosing range in geriatric patients and monitor patients closely.

Adverse Effects

Opioid-induced constipation, dizziness, nausea, vomiting, drowsiness, and respiratory depression are common adverse reactions of hydrocodone-acetaminophen medication. There have been reports of progressive sensorineural hearing loss with chronic hydrocodone/acetaminophen use that is not responsive to high-dose steroids but responsive to cochlear implantation.[2]

As with all opioids, tolerance leading to ever-increasing doses of opioids to maintain the same level of pain control and physical dependence is the most common side effect. Moreover, acute and chronic opioid administration can inhibit antibody and cellular immune responses, natural killer cell activity, cytokine expression, and phagocytic activity. As a result, there are implications of opioids, pointing to an increased incidence of infections in subjects with heroin use disorder.

Opioid users also suffer from endocrine changes in the body, including but not limited to sexual dysfunction, depression, and decreased energy levels, resulting from hypogonadotropic hypogonadism. Also, opioid-induced hyperalgesia is a recently recognized phenomenon after patients experienced increasing pain despite increasing doses of opioids.[2]

Other Adverse Reactions

Central Nervous System: Lethargy, mental clouding, impairment of the physical and mental performance, fear, anxiety, dysphoria, mood changes, dependence
Genitourinary System: Ureteral spasm, urinary retention, spasm of vesical sphincters reported with opiates
Dermatological: Pruritus and skin rash

Contraindications

Contraindications to hydrocodone/acetaminophen include patients with severe respiratory depression, acute or significant bronchial asthma, gastrointestinal obstruction, and anaphylactic reactions due to components of the formula.

As per the manufacturer’s label, several drugs interact with hydrocodone/acetaminophen and caution should be used when they are coadministered.[8][9]

CYP3A4 and CYP2D6 Inhibitors: The coadministration of hydrocodone and acetaminophen with CYP3A4 inhibitors (erythromycin, ketoconazole, and ritonavir) may lead to an increase in the plasma concentration of the hydrocodone and this may result in increased or prolonged opioid effects. These effects may be more pronounced when CYP3A4 and CYP2D6 inhibitors are coadministered with hydrocodone and acetaminophen.
CYP3A4 Inducers: The coadministration of hydrocodone and acetaminophen with CYP3A4 inducers (rifampin, carbamazepine, and phenytoin) may lead to a decrease in the plasma concentration of hydrocodone, and this may result in decreased efficacy.
Benzodiazepines or Other CNS Depressants: The coadministration of hydrocodone and acetaminophen with benzodiazepines or other CNS depressants, due to its additive pharmacologic effect, may lead to an increase in the risk of hypotension, respiratory depression, severe sedation, coma, and death.
Serotonergic Drugs: The coadministration of hydrocodone and acetaminophen with other drugs that affect the serotonergic neurotransmitter system (selective serotonin reuptake inhibitors, serotonin, and norepinephrine reuptake inhibitors, tricyclic antidepressants, triptans, 5-HT3 receptor antagonists) or with drugs that affect the serotonin neurotransmitter system (mirtazapine, trazodone, tramadol cyclobenzaprine, metaxalone, monoamine oxidase inhibitors) may result in serotonin syndrome.
Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: The coadministration of hydrocodone and acetaminophen with other opioid analgesics (butorphanol, nalbuphine, pentazocine) may lead to reducing the analgesic effect of opioids and/or precipitate withdrawal symptoms.
Muscle Relaxants: The coadministration of hydrocodone and acetaminophen with muscle relaxants may enhance the neuromuscular blocking action and may induce a higher degree of respiratory depression.
Diuretics: The coadministration of hydrocodone and acetaminophen with other diuretics may reduce the efficacy of diuretics due to the induction of antidiuretic hormone.
Anticholinergic Drugs: The coadministration of hydrocodone and acetaminophen with anticholinergic drugs may increase the risk of urinary retention and/or severe constipation.

Monitoring

Pain relief and adverse events should undergo frequent assessments. The dosing should start low and slow and titrated up as necessary to obtain adequate analgesia while having minimal side effects.

Hydrocodone is a DEA Schedule II controlled substance and since it has a potential for abuse, misuse, and use disorder. Consequently, it is vital to monitor patients for addiction, abuse, and misuse signs. In addition, patients with a prior history of drug addiction or mental illness have a higher risk of addiction.

For toxicity monitoring, obtain serial liver function tests in patients with severe hepatic disease. Also, monitor serial renal function in elderly patients and patients with severe renal disease.

The clinicians should monitor the following physical findings for the signs of toxicity.

Signs of confusion and over-sedation in the elderly
Addiction, abuse, or misuse behaviors and conditions during treatment
Signs of respiratory depression, especially within 24 to 72 hours of treatment initiation and after dose increases
Signs and symptoms of respiratory depression and sedation in patients susceptible to the intracranial effects of carbon dioxide retention
Severe hypotension at the start of treatment and dose modification
In patients with a history of seizure disorders, monitor for worsened seizure control

Toxicity

Acetaminophen has been associated with fatal hepatic necrosis if taken at doses more than 4 g per day, especially with the ingestion of another acetaminophen-containing product. Furthermore, large doses may cause difficulty with breathing. In overdose, activated charcoal should be the first attempted intervention before N-acetylcysteine (NAC). For patients presenting for 4 hours or later, the serum acetaminophen level should be obtained promptly.

Hydrocodone intake may lead to life-threatening respiratory depression, especially if taken together with benzodiazepines or other CNS depressants. In case of overdose, the first step is to protect the airways and place the patient on invasive ventilation assistance, if needed. The opioid antagonists, nalmefene or naloxone, are specific antidotes for respiratory depression. Opioid antagonists should be avoided in the absence of clinically significant respiratory or circulatory depression. In addition, there is a high risk of precipitating acute opioid withdrawal in an individual who is physically dependent on opioids.

Enhancing Healthcare Team Outcomes

It is not surprising that, without proper barriers and monitoring for the detrimental effects of hydrocodone and acetaminophen intoxication, the morbidity and mortality of using opioid analgesia can be quite substantial. The drug information sheet from the manufacturer emphasizes in bold letters the importance of warning patients of abuse, misuse, and addiction of hydrocodone and acetaminophen, which can lead to overdose and death. Multiple efforts point toward reducing prescription abuse and misuse.

The mitigation of opioid overdose and misuse risk starts from the system-level intervention by clinicians and nurses prescribing narcotics. In addition, the Prescription Drug Monitoring Program and Medicaid managed care lock-in program require that patients receive all scripts from a single prescriber. Although over 55% dropped from the program, the proportion of stable patients, i.e., patients exclusively filled from one prescriber, increased from 31% to 78% at 36 months.[10] [Level 4]

Pharmacists should use formulary management tools to address both opioid overprescribing and overdose. One of them is a prior authorization requirement placed by the insurance companies to verify that the medication is necessary. Cochran et al. conducted a retrospective cohort study evaluating the effects of prior authorization on the rate of abuse and overdose of patients enrolled in the Pennsylvania Medicaid program from 2010 to 2012. The study demonstrated that plans with prior authorization requirements had lower rates of use disorder and overdose.[11] [Level 4]

All in all, there is a battle to reduce the opioid prescription crisis, and still, rates of overdose continue. Numerous interventions show some promise in mitigating this problem, and it truly takes an interprofessional team, including clinicians, mid-level practitioners, nurses, and pharmacists, to achieve this goal. [Level 5]

Review Questions

Access free multiple choice questions on this topic.
Comment on this article.

References

1.: Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014 Jun 01;32(16):1677-90. [PubMed: 24799483]
2.: Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008 Mar;11(2 Suppl):S105-20. [PubMed: 18443635]
3.: Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001 Mar;9(2):84-96. [PubMed: 11305075]
4.: Smith HS. The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain. 2011 Nov-Dec;27(9):824-38. [PubMed: 21677572]
5.: Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23. [PubMed: 24779190]
6.: Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Sep 19, 2022. Hydrocodone. [PubMed: 30000284]
7.: Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Mar 21, 2022. Acetaminophen. [PubMed: 30000253]
8.: Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85. [PMC free article: PMC4150819] [PubMed: 25156930]
9.: Lee D, Stout P, Egdorf D. Houston Cocktail: Driving under influence of hydrocodone, alprazolam, and carisoprodol. Forensic Sci Int. 2021 Apr 28;323:110819. [PubMed: 33964487]
10.: Dreyer TR, Michalski T, Williams BC. Patient Outcomes in a Medicaid Managed Care Lock-In Program. J Manag Care Spec Pharm. 2015 Nov;21(11):1006-12. [PubMed: 26521112]
11.: Cochran G, Gordon AJ, Gellad WF, Chang CH, Lo-Ciganic WH, Lobo C, Cole E, Frazier W, Zheng P, Kelley D, Donohue JM. Medicaid prior authorization and opioid medication abuse and overdose. Am J Manag Care. 2017 May 01;23(5):e164-e171. [PMC free article: PMC6719534] [PubMed: 28810127]

: Disclosure: Manuchehr Habibi declares no relevant financial relationships with ineligible companies.
: Disclosure: Peggy Kim declares no relevant financial relationships with ineligible companies.

Hydrocodone and Acetaminophen – StatPearls

Continuing Education Activity

Objectives:

Identify the mechanism of action of hydrocodone/acetaminophen.
Outline the approved uses for initiating hydrocodone/acetaminophen therapy.
Summarize the adverse event profile and contraindications to using hydrocodone/acetaminophen.
Explain interprofessional team strategies for improving care coordination and communication to advance hydrocodone/acetaminophen therapy, improve outcomes, and minimize adverse events and misuse, especially in light of the ongoing opioid crisis.

Access free multiple choice questions on this topic.

Indications

Mechanism of Action

Hydrocodone is a full opioid agonist that interacts with the mu-receptors and, to a lesser extent, with delta receptors in the body.[3] Activated mu-opioid receptors lead to inhibition of nociceptive pain reflexes and induce profound analgesia without affecting other sensory modalities such as touch. Additionally, activated opioid receptors inhibit neurotransmitter release, including substance P.[3] Hydrocodone reaches maximum serum concentrations within 1 hour with an elimination half-life of 4 to 6 hours.[4] Hydrocodone has to be metabolized by CYP2D6 to its active form, hydromorphone.[3]

Administration

Hydrocodone and acetaminophen combination is available as oral tablet and oral solution formulation.

Hydrocodone bitartrate 5 mg / acetaminophen 300 mg
Hydrocodone bitartrate 5 mg / acetaminophen 325 mg
Hydrocodone bitartrate 7.5 mg / acetaminophen 300 mg
Hydrocodone bitartrate 7.5 mg / acetaminophen 325 mg
Hydrocodone bitartrate 10 mg / acetaminophen 300 mg
Hydrocodone bitartrate 10 mg / acetaminophen 325 mg
Hydrocodone bitartrate 7.5 mg / acetaminophen 325 mg per 15 mL oral solution

Dosing Regimen for Pain Management

The lowest dose necessary for adequate analgesia is recommended and should be titrated individually for each patient taking into account the severity of pain, response, and prior analgesic experience.
For initial oral tablets therapy, the usual adult dose of hydrocodone and acetaminophen ( 5 mg / 300 mg) is one or two tablets every four to six hours as needed for pain. The total daily dosage should not be more than eight tablets.
For initial oral solution therapy, the usual adult dose of solution ( 7.5mg / 325mg per 15 mL) is one tablespoonful (15 mL) every 4 to 6 hours as needed for pain. The total daily dosage for adults should not be more than six tablespoonfuls.
For the conversion from other opioids to hydrocodone and acetaminophen therapy, it is recommended to underestimate the dose of hydrocodone bitartrate and acetaminophen on 24 hours basis for managing an adverse reaction due to the risk of overdose. The relative bioavailability information is unknown for conversion from extended-release hydrocodone to hydrocodone and acetaminophen therapy. So close monitoring for signs of excessive sedation and respiratory depression is recommended. The dose should be titrated on an individual basis. Continuous reevaluation of the dose of hydrocodone and acetaminophen is needed to maintain adequate pain control, minimize adverse effects, and monitor the development of addiction, abuse, or misuse.
For patients who may have a physical dependence on opioids, abrupt discontinuation of hydrocodone and acetaminophen therapy may result in severe withdrawal symptoms, uncontrolled pain, and suicidal tendency.

Specific Patients Population

Patient with Hepatic Impairment: There is no dose adjustment guidance in the manufacturer label for patients with hepatic impairment. However, initiating therapy with the lowest dose with continuous monitoring is recommended in these patients.
Patient with Renal Impairment: There is no dose adjustment guidance in the manufacturer label for patients with renal impairment. However, 26% of hydrocodone and 85% of acetaminophen are eliminated in the urine, so the drug should be used with caution.
Pregnant Women: It is considered as pregnancy category C medicine. There is a US box warning related to pregnancy. During pregnancy, prolonged use of hydrocodone and acetaminophen can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized early and treated accordingly.
Breastfeeding Women: Hydrocodone and Acetaminophen are present in breast milk. The decision to continue or discontinue breastfeeding during therapy should be based on the risk of infant exposure versus the benefits of breastfeeding and treatment to the mother.[6][7]
Pediatric Patients: The dose of hydrocodone for pediatric patients is titrated based on desired analgesic effect. While considering acetaminophen dose, it is recommended to consider the maximum daily dose of acetaminophen from all other sources like OTC, other prescription, or combination products. The maximum daily dose should not exceed 2000 mg for acetaminophen to minimize hepatotoxicity maximum. Based on the information provided in the hydrocodone and acetaminophen oral solution label, dosing should be calculated as 0.27 mL/kg child weight (equivalent to 0.135 mg/kg hydrocodone and 5.85 mg/kg dose of acetaminophen) whenever possible.
Geriatric Patients: For safety and efficacy, it is recommended to start the initial dose at the lower end of the dosing range in geriatric patients and monitor patients closely.

Adverse Effects

Other Adverse Reactions

Central Nervous System: Lethargy, mental clouding, impairment of the physical and mental performance, fear, anxiety, dysphoria, mood changes, dependence
Genitourinary System: Ureteral spasm, urinary retention, spasm of vesical sphincters reported with opiates
Dermatological: Pruritus and skin rash

Contraindications

As per the manufacturer’s label, several drugs interact with hydrocodone/acetaminophen and caution should be used when they are coadministered.[8][9]

CYP3A4 and CYP2D6 Inhibitors: The coadministration of hydrocodone and acetaminophen with CYP3A4 inhibitors (erythromycin, ketoconazole, and ritonavir) may lead to an increase in the plasma concentration of the hydrocodone and this may result in increased or prolonged opioid effects. These effects may be more pronounced when CYP3A4 and CYP2D6 inhibitors are coadministered with hydrocodone and acetaminophen.
CYP3A4 Inducers: The coadministration of hydrocodone and acetaminophen with CYP3A4 inducers (rifampin, carbamazepine, and phenytoin) may lead to a decrease in the plasma concentration of hydrocodone, and this may result in decreased efficacy.
Benzodiazepines or Other CNS Depressants: The coadministration of hydrocodone and acetaminophen with benzodiazepines or other CNS depressants, due to its additive pharmacologic effect, may lead to an increase in the risk of hypotension, respiratory depression, severe sedation, coma, and death.
Serotonergic Drugs: The coadministration of hydrocodone and acetaminophen with other drugs that affect the serotonergic neurotransmitter system (selective serotonin reuptake inhibitors, serotonin, and norepinephrine reuptake inhibitors, tricyclic antidepressants, triptans, 5-HT3 receptor antagonists) or with drugs that affect the serotonin neurotransmitter system (mirtazapine, trazodone, tramadol cyclobenzaprine, metaxalone, monoamine oxidase inhibitors) may result in serotonin syndrome.
Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: The coadministration of hydrocodone and acetaminophen with other opioid analgesics (butorphanol, nalbuphine, pentazocine) may lead to reducing the analgesic effect of opioids and/or precipitate withdrawal symptoms.
Muscle Relaxants: The coadministration of hydrocodone and acetaminophen with muscle relaxants may enhance the neuromuscular blocking action and may induce a higher degree of respiratory depression.
Diuretics: The coadministration of hydrocodone and acetaminophen with other diuretics may reduce the efficacy of diuretics due to the induction of antidiuretic hormone.
Anticholinergic Drugs: The coadministration of hydrocodone and acetaminophen with anticholinergic drugs may increase the risk of urinary retention and/or severe constipation.

Monitoring

Pain relief and adverse events should undergo frequent assessments. The dosing should start low and slow and titrated up as necessary to obtain adequate analgesia while having minimal side effects.

For toxicity monitoring, obtain serial liver function tests in patients with severe hepatic disease. Also, monitor serial renal function in elderly patients and patients with severe renal disease.

The clinicians should monitor the following physical findings for the signs of toxicity.

Signs of confusion and over-sedation in the elderly
Addiction, abuse, or misuse behaviors and conditions during treatment
Signs of respiratory depression, especially within 24 to 72 hours of treatment initiation and after dose increases
Signs and symptoms of respiratory depression and sedation in patients susceptible to the intracranial effects of carbon dioxide retention
Severe hypotension at the start of treatment and dose modification
In patients with a history of seizure disorders, monitor for worsened seizure control

Toxicity

Enhancing Healthcare Team Outcomes

Review Questions

Access free multiple choice questions on this topic.
Comment on this article.

References

1.: Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014 Jun 01;32(16):1677-90. [PubMed: 24799483]
2.: Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008 Mar;11(2 Suppl):S105-20. [PubMed: 18443635]
3.: Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001 Mar;9(2):84-96. [PubMed: 11305075]
4.: Smith HS. The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain. 2011 Nov-Dec;27(9):824-38. [PubMed: 21677572]
5.: Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23. [PubMed: 24779190]
6.: Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Sep 19, 2022. Hydrocodone. [PubMed: 30000284]
7.: Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Mar 21, 2022. Acetaminophen. [PubMed: 30000253]
8.: Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85. [PMC free article: PMC4150819] [PubMed: 25156930]
9.: Lee D, Stout P, Egdorf D. Houston Cocktail: Driving under influence of hydrocodone, alprazolam, and carisoprodol. Forensic Sci Int. 2021 Apr 28;323:110819. [PubMed: 33964487]
10.: Dreyer TR, Michalski T, Williams BC. Patient Outcomes in a Medicaid Managed Care Lock-In Program. J Manag Care Spec Pharm. 2015 Nov;21(11):1006-12. [PubMed: 26521112]
11.: Cochran G, Gordon AJ, Gellad WF, Chang CH, Lo-Ciganic WH, Lobo C, Cole E, Frazier W, Zheng P, Kelley D, Donohue JM. Medicaid prior authorization and opioid medication abuse and overdose. Am J Manag Care. 2017 May 01;23(5):e164-e171. [PMC free article: PMC6719534] [PubMed: 28810127]

: Disclosure: Manuchehr Habibi declares no relevant financial relationships with ineligible companies.
: Disclosure: Peggy Kim declares no relevant financial relationships with ineligible companies.

Norco 5/325 (Hydrocodone Bitartrate & Acetaminophen): Uses, Dosage, Side Effects, Interactions, Warning

Indications and dosage

Side effects and drug interactions

Warnings

Precautions

Overdose and contraindications

Clinical pharmacology

Medication guide

Product description

What is Norco 5/325 and how is it used?

Norco 5/325 (hydrocodone acetaminophen and bitartrate) is an opioid analgesic and antitussive (cough suppressant) combined with an antipyretic and analgesic and is used to treat moderate to fairly severe pain. Norco 5/325 is available as a generic .

What are the side effects of Norco 5/325?

Common side effects of Norco 5/325 include:

lightheadedness,
nausea,
vomiting,
constipation,
upset stomach,
headache dizziness or drowsiness,
restlessness,
Headache,
mood changes,
blurred vision,
ringing in the ears, or
dry mouth.

DESCRIPTION

NORCO (hydrocodone bitartrate and acetaminophen) is supplied as tablets for oral use.

Hydrocodone bitartrate is an opioid analgesic and antitussive and occurs as fine white crystals or crystalline powder. It is affected by light. The chemical name is 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It has the following structural formula:

Acetaminophen, a 4-hydroxyacetanide, slightly bitter, white, odorless crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. Has the following structural formula:

Oral NORCO is available in the following dosages:

Hydrocodone

Acetaminophen Bitartrate

NORCO 7.5 / 325 7.5 mg 325 mg
NORCO 10/325 10 mg 325 mg

In addition, each tablet contains the following inactive ingredients: croscarmellose sodium, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch and stearic acid; 7.5mg/325mg tablets include FD&C Yellow #6 Aluminum Lake, 10mg/325mg tablets include D&C Yellow #10 Aluminum Lake. Meets USP 1 dissolution test.

Indications and dosage

INDICATIONS

NORCO is indicated for the relief of moderate to moderately severe pain.

DOSAGE AND ADMINISTRATION

Dosage should be adjusted according to the degree of pain and the response of the patient. However, it should be borne in mind that tolerance to hydrocodone may develop with continued use and that the frequency of adverse effects is dose dependent.

The usual adult dose is one tablet every four to six hours as needed for pain relief. The total daily dosage should not exceed 6 tablets.

HOW SUPPLIED

NORCO 7.5 / 325 Available as capsules of light orange tablets, split in half on one side and embossed with “NORCO 729” on the other side. Each tablet contains 7.5 mg hydrocodone bitartrate and 325 mg acetaminophen. They are supplied as follows:

Bottles of 30
Bottles of 100 pcs.
500 bottles

what is an inner ear infection

NORCO 10/325 Available as yellow capsule-shaped tablets, halved on one side and embossed with “NORCO 539” on the other side. Each tablet contains 10 mg hydrocodone bitartrate and 325 mg acetaminophen. They are supplied as follows:

Bottles of 100 pcs.
Bottles of 500

Store at 20°-25°C (68°-77°F). [See Room Temperature Controlled USP .]

Dispense in a tight, light-resistant container with a child-proof lid.

Watson Pharma, Inc., a subsidiary of Watson, Pharmaceuticals, Inc., Corona, CA 92880, USA, 14716. Revised: July 2007 Cardinal Health, Zanesville, OH 43701.

Side effects and drug interactions

SIDE EFFECTS

The most common adverse reactions are dizziness, sedation, nausea and vomiting. These effects appear to be more pronounced in outpatients than in general patients, and some of these adverse reactions may be alleviated by lying down.

Other adverse reactions include:

Central nervous system: Drowsiness, clouding of consciousness, lethargy, impaired mental and physical performance, anxiety, fear, dysphoria, mental dependence, mood changes.

Gastrointestinal: Prolonged administration of NORCO may cause constipation.

Genitourinary system: Spasm of the ureter, spasm of the vesical sphincter and urinary retention have been reported with opiates.

Respiratory depression: Hydrocodone bitartrate may cause dose-dependent respiratory depression by acting directly on the respiratory centers of the brainstem (see OVERDOSE ).

Special Senses: Hearing impairment or irreversible loss has been reported predominantly in patients with chronic overdose.

Dermatological: Skin rash, pruritus.

The following adverse events can be considered as potential effects of paracetamol: allergic reactions, rash, thrombocytopenia, agranulocytosis. Possible effects of high dosages are listed in the OVERDOSE section.

Drug abuse and dependence

Controlled substance

NORCO is classified as a Schedule III controlled substance.

Abuse and dependence

Mental dependence, physical dependence and tolerance may develop with repeated drug use; therefore, this product should be prescribed and administered with caution. However, psychic dependence is unlikely to develop with short-term use of NORCO for the treatment of pain.

Physical dependence, a condition that requires continued drug use to prevent withdrawal, only becomes clinically significant after several weeks of continuous drug use, although some mild degree of physical dependence may develop after a few days of use. drug therapy. Tolerability, in which higher and higher doses are required to obtain the same degree of pain relief, first manifests itself in a reduction in the duration of the analgesic effect, and then in a decrease in the intensity of pain relief. The rate of development of tolerance in different patients is different.

DRUG INTERACTIONS

Patients receiving other narcotics, antihistamines, antipsychotics, sedatives, or other CNS depressants (including alcohol) concomitantly with NORCO may exhibit additive CNS depression. If combination therapy is contemplated, the dose of one or both agents should be reduced.

The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of the antidepressant or hydrocodone.

Interactions with drugs / laboratory tests

Acetaminophen may give false positive results for 5-hydroxyindoleacetic acid in urine.

Warnings

WARNINGS

Respiratory depression

At high doses or in sensitive patients, hydrocodone may cause dose-dependent respiratory depression by acting directly on the respiratory center of the brainstem. Hydrocodone also affects the center that controls the respiratory rhythm and can cause irregular and periodic breathing.

Head trauma and increased intracranial pressure

The respiratory depressant effects of drugs and their ability to increase cerebrospinal fluid pressure may be markedly exaggerated in the presence of head trauma, other intracranial lesions, or a pre-existing increase in intracranial pressure. In addition, drugs cause adverse reactions that may obscure the clinical course of patients with head injuries.

Acute diseases of the abdominal cavity

Drug administration may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

Precautions

PRECAUTIONS

General

Special Risk Patients

As with any narcotic analgesic, NORCO should be used with caution in elderly or debilitated patients and in patients with severe hepatic or renal impairment, hypothyroidism , illness Addison, prostatic hypertrophy or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.

Cough reflex

Hydrocodone suppresses the cough reflex; As with all drugs, caution should be exercised when using NORCO in the postoperative period and in patients with pulmonary disease.

Laboratory tests

In patients with severe liver or kidney disease, the effect of therapy should be monitored by serial tests of liver and/or kidney function.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Adequate studies have not been conducted in animals to determine whether hydrocodone or acetaminophen has the potential to cause carcinogenesis, mutagenesis or impairment of fertility.

azo yeast side effects intestinal inflammation

Pregnancy

Teratogenic effects

Pregnancy category C

There are no adequate and well-controlled studies in pregnant women. NORCO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Non-teratogenic effects

Infants born to mothers who regularly took opioids prior to birth will be physically dependent. Withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, rapid breathing, rapid stools, sneezing, yawning, vomiting, and fever. The severity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on how best to deal with withdrawal symptoms.

Handling and Delivery

As with all drugs, administration of this product to the mother shortly before delivery may result in some degree of respiratory depression in the neonate, especially at higher doses.

Nursing mothers

Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on infants is unknown. It is not known if hydrocodone is excreted in breast milk. Since many drugs are excreted in breast milk and because of the potential for serious adverse reactions in nursing infants to hydrocodone and acetaminophen, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use

Safety and efficacy in pediatric patients have not been established.

Geriatric Use

Clinical studies of hydrocodone bitartrate 5 mg and acetaminophen 500 mg did not include sufficient numbers of subjects aged 65 years and over to determine if they respond differently than younger subjects. Other reported clinical experience has found no difference in response between older and younger patients. In general, dose selection for the elderly patient should be cautious, usually starting at the lower end of the dosing range, reflecting a greater incidence of decreased hepatic, renal, or cardiac function, as well as concomitant disease or other drug therapy.

Hydrocodone and the main metabolites of acetaminophen are known to be primarily excreted by the kidneys. Thus, the risk of toxic reactions may be higher in patients with impaired renal function due to accumulation of the parent compound and/or metabolites in plasma. Because older patients are more likely to have decreased renal function, care should be taken in dose selection and it may be beneficial to monitor renal function.

Hydrocodone may cause confusion and excessive sedation in the elderly; Elderly patients should generally be initiated on low doses of hydrocodone bitartrate and acetaminophen tablets and monitored closely.

Overdose and contraindications

OVERDOSAGE

Acute overdose may cause toxic effects of hydrocodone or acetaminophen.

Signs and symptoms

Hydrocodone

Severe hydrocodone overdose is characterized by respiratory depression (decreased respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), severe drowsiness progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia, etc. hypotension. In severe overdose, sleep apnea, circulatory failure, cardiac arrest and death can occur.

Acetaminophen

Paracetamol overdose: Dose-dependent, potentially fatal liver necrosis is the most serious side effect. Renal tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur.

Early symptoms of a potentially hepatotoxic overdose may include nausea, vomiting, sweating and general malaise. Clinical and laboratory evidence of liver toxicity may not appear until 48-72 hours after ingestion.

In adults, liver toxicity has rarely been reported with acute overdoses of less than 10 grams or fatalities with doses of less than 15 grams.

Care

A single or multiple overdose of hydrocodone and acetaminophen is a potentially lethal overdose of polydrug addiction, so consultation with your local poison control center is recommended.

side effects of doxycycline treatment of Lyme disease

Immediate treatment includes support for cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced mechanically or with ipecac syrup if the patient is alert (adequate pharyngeal and laryngeal reflexes). Activated charcoal by mouth (1 g/kg) should be taken after a gastric emptying. The first dose should be accompanied by appropriate laxatives. If repeated doses are used, the laxative may be added with other doses as needed. Hypotension is usually hypovolemic and must be fluid-responsive. Vasopressors and other supportive measures should be used as directed. A cuffed endotracheal tube should be inserted prior to gastric lavage in an unconscious patient and, if necessary, to provide assisted breathing.

Particular attention should be paid to maintaining adequate ventilation. In severe cases of intoxication, peritoneal dialysis or, preferably, hemodialysis may be considered. If hypoprothrombinemia occurs due to an overdose of acetaminophen, vitamin K should be given intravenously.

Naloxone, a drug antagonist, may reverse respiratory depression and coma associated with opioid overdose. Naloxone hydrochloride 0.4 mg to 2 mg is administered parenterally. Because the duration of action of hydrocodone may exceed that of naloxone, the patient should be monitored closely and repeated doses of the antagonist administered as needed to maintain adequate respiration.

The narcotic antagonist should not be used in the absence of clinically significant respiratory or cardiovascular depression.

If the dose of acetaminophen could exceed 140 mg/kg, acetylcysteine should be administered as soon as possible. Serum levels of paracetamol should be determined, as levels four or more hours after ingestion help predict paracetamol toxicity. Do not wait for acetaminophen test results before starting treatment. First you need to get liver enzymes, and then repeat them every 24 hours.

Methemoglobinemia greater than 30% should be treated with methylene blue by slow intravenous administration.

The adult toxic dose of paracetamol is 10 g.

CONTRAINDICATIONS

NORCO should not be used in patients with a history of hypersensitivity to hydrocodone or acetaminophen.

Patients with hypersensitivity to other opioids may show cross-sensitivity to hydrocodone.

Clinical pharmacology

CLINICAL PHARMACOLOGY

Hydrocodone is a semi-synthetic narcotic analgesic and antitussive with many actions qualitatively similar to those of codeine. Most of them affect the central nervous system and smooth muscles. The exact mechanism of action of hydrocodone and other opiates is unknown, although it is thought to be related to the existence of opiate receptors in the central nervous system. In addition to pain relief, drugs can cause drowsiness, mood changes, and clouding of the mind.

The analgesic action of paracetamol is associated with peripheral effects, but the specific mechanism has not yet been determined. The antipyretic effect is transmitted through the hypothalamic heat regulation centers. Acetaminophen inhibits prostaglandin synthetase. Therapeutic doses of paracetamol have little effect on the cardiovascular or respiratory systems; however, toxic doses can cause circulatory failure and shallow breathing.

Pharmacokinetics.

The behavior of the individual components is described below.

Hydrocodone

After oral administration of 10 mg hydrocodone to five adult males, the mean peak concentration was 23. 6 ± 5.2 ng/mL. Peak serum levels were reached at 1.3 ± 0.3 hours and the half-life was 3.8 ± 0.3 hours. Hydrocodone exhibits a complex metabolic pattern including O-demethylation, N-demethylation, and 6-ketoreduction to the corresponding 6-α- and 6-β-hydroxy metabolites. See OVERDOSE for toxicity information.

Acetaminophen

Acetaminophen is rapidly absorbed from the gastrointestinal tract and distributed to most body tissues. The plasma half-life ranges from 1.25 to 3 hours, but may increase with liver damage and after overdose. Excretion of paracetamol occurs mainly due to metabolism (conjugation) in the liver and subsequent excretion of metabolites by the kidneys. Approximately 85% of an oral dose is excreted in the urine within 24 hours of ingestion, primarily as the glucuronide conjugate with small amounts of other conjugates and unchanged drug. see OVERDOSE for toxicity information.

Medication Guide

PATIENT INFORMATION

Hydrocodone, like all drugs, may impair the mental and/or physical abilities required to perform potentially hazardous tasks such as driving a car or operating machinery; patients should be warned accordingly.

Alcohol and other CNS depressants may cause additional CNS depression when taken with this combination product and should be avoided.

Hydrocodone may be habit-forming. Patients should only take the drug for as long as it is prescribed, in the prescribed amounts, and no more frequently than prescribed.

Take the drug only for as long as it is prescribed, in the prescribed amounts and no more often than prescribed.

Norco vs Vicodin – Difference & Comparison – Health

Video: The Other Side of Vicodin

Comparison Chart
Composition
Dosage
Side effects
Warnings
Addiction
Classification
Prescriptions

Norco and Vicodin are common narcotic pain relievers that consist of two active ingredients, acetaminophen and hydrocodone. The levels of these two ingredients differ for each drug; Norco contains higher levels of hydrocodone while Vicodin contains higher levels of acetaminophen. The difference in these levels determines dosage recommendations and causes various side effects.

Comparison chart

Comparison chart Norco and Vicodin
	Norco	Vicodin
	current rating 2.8 / 5 (178 ratings)	current rating 3.31 / 5 (425 ratings)
Generic name	Acetaminophen and hydrocodone	Acetaminophen and hydrocodone
Dose	1 every 4-6 hours as needed	1-2 every 4-6 hours as needed
Side effects	Drowsiness, upset stomach, constipation, headache, blurred vision, dry mouth, urticaria, difficulty breathing, swelling of the face, confusion, itching, slow heartbeat	Dizziness, drowsiness, mild nausea, constipation , blurred vision, dry mouth, headache, mood changes, tinnitus
Uses	Moderate to severe pain relief	Moderate to severe pain relief
Dependence	Addictive	Addictive
Overdose	May cause liver damage and death	May cause liver damage and death
Generic available	yes	yes
Manufacturer	Actavis	AbbVie
Other brands	Hycet, Lorcet, Lorcet Plus, Lortab, Maxidone, Norco, Vicodin, Vicodin ES, Vicodin HP, Zamicet and Zydone	Anexsia, Co-Gesic, Hycet, Liquicet, Lorcet, Maxidone, Norco, Polygesic, Stagesic, Xodol, Zemicet, Zolvit, Zydone 75
Website	http ://www. actavis.com/	http://www.vicodin.com/, http://www.abbvie.com/

Composition

There are usually two types of Norco tablets: Norco 7.5/325 and Norco 10/325. The first consists of 7.5 mg of hydrocodone bitartrate and 325 mg of acetaminophen; the second simply contains an additional 2.5 mg of hydrocodone. Regardless of the type of Norco tablet, each Norco tablet contains a higher level of hydrocodone than a Vicodin tablet.

A typical Vicodin tablet consists of 5 mg hydrocodone bitartrate and 500 mg acetaminophen containing significantly higher levels of acetaminophen than Norco tablets.

Dosage

The usual adult dose of Norco is 1 tablet every four to six hours as needed, although actual recommendations are adjusted based on pain severity and patient response. The daily dosage should not exceed 6 tablets.

The usual adult dose of Vicodin is 1-2 tablets every four to six hours as needed, also varying according to the patient’s response. It is noteworthy that more Vicodin tablets can be used at one time than Norco tablets. The daily dose is also slightly higher than Norco’s, as Vicodin’s recommendations state that it should not exceed 8 tablets per day, while Norco only allows up to 6.

Overdose

Overdose of Norco and Vicodin can cause liver damage and death. Overdose signs include nausea, vomiting, abdominal pain, sweating, and confusion. Later symptoms include upper stomach pain, dark urine, and yellowing of the skin and eyes (jaundice).

Side effects

Side effects for each of these drugs are almost the same and include drowsiness, upset stomach, constipation, headache, blurred vision, dry mouth, hives, difficulty breathing, swelling of the face, confusion, itching, and slow heartbeat.

Vicodin is slightly different from Norco in that the chance of stomach problems is much higher in patients taking Vicodin due to higher paracetamol levels. Some doctors will change prescriptions to Norco for patients who have stomach problems while taking Vicodin.

Warnings

Norco and Vicodin have the same important warnings. Those who have ever had alcoholic liver disease or who have consumed more than three alcoholic drinks a day should not take this medicine without consulting a doctor. People taking them should not drink alcohol, as this increases the risk of liver disease. These drugs can also cause breathing problems and addiction/withdrawal symptoms in newborns, so pregnant women should check with their doctor before taking them. Neither should be taken with other narcotic pain relievers, sedatives, hypnotics, or muscle relaxants.

Addiction

Due to the mood-altering effects of Norco and Vicodin, both drugs are addictive. If people suddenly stop taking these drugs after long-term use, they may suffer withdrawal symptoms. None of the substances is significantly more addictive than the other, since their composition is almost the same.

However, due to the higher concentration of hydrocodone in Norco tablets, patients taking these tablets may potentially experience the addictive properties of the previously used drug.